Recently there has been a drive from various stakeholders involved in how new medicines or medical devices gain access to the UK market to introduce changes that reflects modern needs of the country. This drive for change generated discussions and some recommendations on how National Institute for Health and Care Excellence should operate in the future. Amongst many important recommendations one is putting greater emphasis on Real World Evidence (RWE), something that TreatSMA has constantly campaigned about and pushed during the Spinraza Appraisal.
The changes and reviewed offered by APPG on Access to Medicines and Medical Devices is welcomed by TreatSMA as a positive step forward.
Click here to read the full report.